What Researchers Did
Researchers conducted a systematic review and meta-analysis to evaluate available therapeutic interventions for hidradenitis suppurativa by searching four electronic databases.
What They Found
Adalimumab, given weekly, was superior to placebo, reducing the Sartorius score by a standardized mean difference of -0.32 (P < 0.0001) and pain with a risk ratio of 1.42 (P = 0.02). Based on the quality of evidence, adalimumab and laser therapy were identified as the most recommended treatments for hidradenitis suppurativa.
What This Means for Canadian Patients
Canadian patients with hidradenitis suppurativa may benefit from discussing adalimumab or laser therapy with their healthcare providers. These treatments can help manage lesions and associated pain, potentially improving their quality of life.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The abstract does not explicitly detail study limitations, but meta-analyses are often limited by the quality and heterogeneity of the included primary studies.